Bin Lu, Ph.D.

_______________________________________________________________ 3 Blackfan Circle, CLS room 447, MA 02115 Beth Israel Deaconess Medical Center, Harvard Medical School Mobile 857.225.0629 | Office Phone 617.735.2105 | Fax 617.735.2110 Email: bl1ae53b8@westpost.net; blu@bidmc.harvard.edu CAREER TARGETS A highly motivated and innovative scientist with detailed knowledge of gene scre ening, cell/molecular biology and cancer biology is seeking for a scientist/seni or Scientist or research investigator position in the pharmaceutical or diagnost ic industry. QUALIFICATIONS Experienced at gene expression profiling in cancer using microarray, real time P CR and branched DNA techniques. Experience in designing the gene biomarker chip for prostate cancer detection us ing clinical whole urine. Experienced at evaluation of cancer biomarker targets using biochemical, cell or tissue based assay. Highly motivated and innovative scientist with detailed knowledge of oncology an d cell signaling. Proficiency with in vitro and in vivo cancer biology assays. Comprehensive expertise in molecular/cell biology experiment design, execution, data interpretation and technical troubleshooting. Proven ability to perform multi-tasks efficiently and independently. Strong interpersonal skills to supervise research associates and work in a teamoriented multidisciplinary environment. Excellent oral and written communication skills. TECHNICAL SKILLS Molecular Biology Gene expression analysis. Cancer biomarker investigation and evaluation. Designing and performing transient (siRNA), stable (shRNA), and inducible (Tet O N/OFF) RNA interference (RNAi). Extensive experience with modern techniques in molecular biology including: DNA, RNA isolation, PCR, real-time PCR (SYBR and Taqman) and branched DNA analysis. Western, ELISA, and immunohistochemistry techniques. Gel purification, recombinational and PCR cloning and subcloning cDNA into diffe rent expression vectors. Microarray samples preparation and data analysis. Familiar with bioinformatics database (BLAST, Oncomine) Urine cell pellet and RNA preparation from patients and gene expression analysis . Cancer and Cell Biology Mammalian cell culture, cell line generation, reporter cell line construction, t ransfection, and lentiviral infection. Development of in vitro cell-based assays. Analysis of cellular surface or intracellular protein level using western blot, ELISA, and flow cytometry based assays. Analysis of cellular cycle and cell types using flow cytometry and separating ce lls using FACS. Isolation and analysis of primary tumor samples. Tissue dissection. in vivo tumor models in scid mouse and transgenic mouse. Human prostatectomy samples (OCT or PPFE) processing. Gene and protein expressio n analysis from human tissue and urine samples. COMPUTER SKILLS

Extensive experience with computer including: Graphhic, Imaging data analysis; M S Word, Excel, PowerPoint, and Photoshop; Microarray data analysis. C++ and basi c molecular modeling skills including amber, InsightII and Syby1. EDUCATION Ph.D., Department of Basic Pharmaceutical Sciences, West Virginia University, USA B.S., Department of Biology (major in biochemistry), Anhui University, China RESEARCH EXPERIENCES AND ACHIEVEMENTS Harvard Medical School, Beth Israel Deaconess Medical Center, 2006-pres ent Postdoctoral Research Fellow (Dr. Martin Sandas translational research lab, a to p lab in Early Detection Research Network) Evaluate differentially expressed genes in prostate cancer as either biomarkers for cancer detection and as targets for improving prostate cancer immunotherapy. Human as well as mouse models are used in our lab. The role of Sim2 gene in prostate cancer progression. Design and evaluate the potential prostate cancer detection biomarkers in patien t urine and tissues using state of art technique from collaborated company. Quantitative evaluation of prostate cancer markers ERG, TMPRSS2-ERG fusion gene, AMACR, HPSN, PSA, CAMKK2 in human clinical samples. Secretory prostate tumor associated antigen identification and validation. Mechanism study of specific cancer related genes in human prostate cancer such a s Sim2 gene. West Virginia University, School of Pharmacy, 2000-2005 Ph.D. candidate (Dr. Yon Rojanasakuls lab) Investigated the role of Phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (PKB) pathway in Fas-mediated programmed cell death (apoptosis) and carcinogenesis. Conduct a study of the molecular mechanism of cellular FLICE-inhibitory protein (c- FLIP) signaling and its regulation of Fas (CD95)-induced NF-B activation and apoptosis. Elucidated the role of NF-B and TNF- in death receptor-mediated apoptosis and inflammatory response. Developed a novel delivery system for gene therapeutics using signal peptide fus ion proteins. LEADERSHIP AND COMMUNITY SERVICE 2007-2009: Founder and vice president of Chinese Scholar and Scientist Asso ciation at Harvard Medical School (CSSA at HMS). Organize and co -organize multiple activities such as symposium, career developmen t salon series, and new year party with around 1500 memberships. HONORS AND AWARD Department of Defense (DOD) Prostate Cancer Research Program (PCRP) Training Aw ard, receiving $119,980 as a Principal Investigator through 2009-2011

American Association of Pharmaceutical Scientists (AAPS) Graduate Student Sympo sium Award in Biotechnology, selected as one of the 4 individuals to speak in B iotechnology section and received a $250 honorarium in 2005 Outstanding thesis (2 awardees out of 60 graduates) in Department of Biology, A nhui University in 1996 MEMBERSHIP Active member of American Association of Immunologists (AAI), 2010-present Associate Member of American Association of Immunologists (AAI), 2006-2009 Active member of American Association for Cancer Research (AACR), 2010-present Member of American Association for Cancer Research (AACR), 2006-2009 Member of American Association of Pharmaceutical Scientists, 2001-2006 MANUSCRIPTS UNDER SUBMISSION/PREPARATION 1. Lu B, Asara JM, Sanda MG, and Arredouani MS. The role of the transcription fa ctor SIM2 in prostate cancer. Submitted to Plos one (under revision). 2011 2. Lu B, Chipman J, McMaster GK, Ma YQ, Regan M, and Sanda MG. Novel prostate ca ncer biomarkers revealed by branched DNA technique. 2011 PUBLICATIONS 1. Arredouani MS*, Lu B*, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the Transcription Factor Single-minded 2 homologue 2 as a Potential Biomarker and Immunotherapy Target i n Prostate Cancer. Clin Cancer Res. 15(18): 5794-802, 2009 (* equal contribution to the project) 2. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. Urology 74(5): 1156-61, 20 09 3. Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS. Gene expression profile of mouse prostate t umors reveals dysregulations in major biological processes and identifies potent ial murine targets for preclinical development of human prostate cancer therapy. Prostate 68(14): 1517-30, 2008 4. Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG. F as-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mo use model of prostate cancer. Cancer Immunol Immunother 57(9); 1357-65, 2008 5. Lu B, Wang L, Stehlik C, Medan D, Huang C, Hu S, Chen F, Shi X and Rojanasaku l Y. Phosphatidylinositol-3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal C1 41 cells. J. Immunology. 176(11): 6785-93, 2006 6. C